A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata

Inclusion Criteria:

• Male or nonpregnant, nonlactating female subject aged 18 to 75 years (inclusive) atthe time of informed consent.
• Subjects with a clinical diagnosis of AA defined as having a SALT score ≥ 50 and inwhich the current episode of hair loss is > 24 weeks (without evidence of spontaneousterminal hair regrowth ≥ 10% within 24 weeks at the time of screening and baseline),but ≤ 8 years (from onset of current episode).

Exclusion Criteria:

• Concomitant active systemic diseases (except stable thyroid diseases) that may causehair loss (eg, lupus erythematosus, systemic sclerosis, celiac disease) that couldinterfere with the Investigators' ability to evaluate the subject's response totherapy.
• Subject's cause of hair loss is indeterminable and/or in addition to AA they haveconcomitant causes of alopecia, such as traction alopecia, cicatricial alopecia,lichen planopilaris, frontal fibrosing alopecia, advanced androgenetic alopecia (ie,Ludwig Type III or Norwood-Hamilton Stage ≥ V), telogen effluvium, trichotillomania,or diffuse AA (alopecia areata incognita).
• Known or suspected congenital or acquired immunodeficiency state, or condition thatwould compromise the subject's immune status (eg, history of splenectomy).